Germany's IQWiG backs Bristol-Myers' Opdivo in melanoma; Pfizer ALL med inotuzumab gets 'breakthrough' status;

> German cost-effectiveness gatekeepers decided that Bristol-Myers Squibb's ($BMY) immuno-oncology treatment Opdivo offers an "added benefit" over previous treatments, particularly in men. Report

> Pfizer ($PFE) scored the FDA's breakthrough therapy designation on inotuzumab, its experimental drug for acute lymphoblastic leukemia, the third of Pfizer's cancer candidates to win that status. Report

> Allergan ($AGN) expanded its portfolio of dry-eye remedies with the launch of the over-the-counter Refresh Optive Gel Drops. Release

> LEO Pharma won FDA approval for Enstilar, its topical foam treatment for psoriasis vulgaris in patients 18 and older. Report

And Finally... Novartis' ($NVS) new affordable-drugs scheme for emerging markets launched in Kenya. Release

Suggested Articles

Novartis is taking its MBC campaign to Instagram with a newly launched video series as part of the five-year “Make Your Dialogue Count” effort.

FDA researchers uncover more concerns and fears among front-line workers and minority groups about a COVID-19 vaccine.

Leo Pharma's latest "hackathon" brought together scientists and entrepreneurs to find dermatology solutions for people of color.